Issuance of new shares in connection with a directed issue
Issuance of new shares in connection with a directed issue
Initiator Pharma A/S, company reg. (CVR) no. 37663808,(“Initiator” or the “Company”) has today issued new shares in connection with the capital increase directed at Annika Espander, the Company´s strategic advisor.
With reference to the company announcement dated 5 July 2022, the Company’s share capital has today been increased by a total of nominally DKK 34,999.965 divided into 333,333 shares of nominally DKK 0.105 (the “New Shares”) as a result of the directed issue to Annika Espander. The shares have been issued at market value without pre-emption rights for the existing shareholders subject to the board authorisation in article 4b in the Company’s articles of association. The capital increase has been registered with the Danish Business Authority.
The New Shares are subject to the same rights as existing shares under the Company’s articles of association and is expected to be admitted to trading on Nasdaq First North Growth Market under the existing ISIN code DK0060775872 within a few days.
After the capital increase, the total nominal value of the Company’s share capital amounts to nominally DKK 4,924,338.4 divided into 46,898,461 shares of nominally DKK 0.105 each corresponding to 46,898,461 votes.
The Company’s updated articles of association have been made available on the Company’s website.